Gene Expression Analysis in MOTN-1 Cell Line after Treating with New Development Aptamer

Abstract

Among age-related morality in humans, cancer stands at 2nd leading cause and this is why the ability to suppress carcinogenesis has got the cancer prevention and treatment researchers working hard on this. Leukemia (cancer of bone marrow and blood), is most commonly characterized by uncontrolled proliferation of some blood cells, in this case leukocytes. There are generally four types of leukemia: acute myelogenous, chronic myelogenous, acute lymphocytic and chronic myelogenous. There are quite a few different leukemia cell lines and among them, the MOTN-1 cell line was derived from acute lymphoblastic leukemia. Moreover, the MOTN-1 cells are commonly described a highly undifferentiated leukemia cells. In this study, we evaluated the effects of SIRT1 activation by aptamer (Aptamer are single strand DNA or RNA molecules, selected by an iterative process known as Systematic Evolution of Ligands by Exponential Enrichment SELEX) on viability of MOTN-1 cancer cell line as an anticancer drug and analysed the gene expression profiles of MOTN-1 cells treated with aptamer and untreated cells by cDNA microarray analysis and RT-PCR to give us more details about the molecular mechanisms underlying aptamer- induced carcinogenesis, including leukaemia. The results demonstrate that aptamer is extremely efficient tools for anticancer activity on ALL by inhibited 91% of these cancer cells at 10 µM aptamer after 72 hours with IC50 = 3.5 μM. Besides that, we at first identified 13 genes with expression changed by aptamer treatment. For this set of genes, 11 of these were up-regulated and two were down-regulated by more than 3-fold, respectively. As a result, pharmacological activation of SIRT1 enhanced cell death suggesting a tumor suppressive function of aptamer and may be used in the future for cancer treatment.